Gilead Sciences Inc. (NASDAQ:GILD) reported Total revenues of $7.3 billion were no comparison to the year-ago figure of $3.1 billion. Quarterly revenues were above the Zacks Consensus Estimate of $6.7 billion. Full-year 2014 revenues increased 122.2% to $24.9 billion, topping the Zacks Consensus Estimate of $24.3 billion. Earnings (including stock-based compensation expenses) increased to $7.91 per share, way above $1.93 per share in the year-ago period. Earnings were also above the Zacks Consensus Estimate of $7.72 per share. On Wednesday shares of Gilead Sciences Inc. (NASDAQ:GILD) closed at $98.43. Company’s sales growth for last 5 years was 16.00% and EPS growth for next 5 years is recorded as 33.42%.
Achillion Pharmaceuticals (NASDAQ:ACHN) CFO Mary Kay Fenton sold 13,125 shares of the stock on the open market in a transaction dated Friday, January 23rd. The shares were sold at an average price of $16.00, for a total transaction of $210,000.00. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) in last trading activity decreased -16.90% to close at $12.05. Company weekly performance is -18.64% while its quarterly performance stands at -0.58%. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is -28.57% away from its 52 week high.
Pacific Biosciences of California Inc. (NASDAQ:PACB) on Tuesday reported a loss of $19 million in its fourth quarter. On a per-share basis, the Menlo Park, California-based company said it had a loss of 26 cents. The maker of genetic analysis technology posted revenue of $16.9 million in the period. On last trading day Pacific Biosciences of California, Inc. (NASDAQ:PACB) decreased -18.25% to close at $6.81. Its volatility for the week is 7.73% while volatility for the month is 6.30%. PACB’s sales growth for past 5 years was 99.20% and its EPS growth for past 5 years was -7.70%. Pacific Biosciences of California, Inc. (NASDAQ:PACB) monthly performance is -12.02%.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) and Bristol Myers-Squibb (BMY) on 29 January announced the initiation of a Phase 1/2 dose escalation and cohort expansion study examining the investigational combination of varlilumab, Celldex’s CD27 targeting investigational immune-activating antibody and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab). Celldex Therapeutics, Inc. (NASDAQ:CLDX) has 0.28% insider ownership while its institutional ownership stands at 91.10%. In last trading activity company’s stock closed at $19.12.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), on 2 February announced topline Phase 3 results from the GIFT-1 study, AbbVie’s investigational, all-oral, ribavirin-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBT/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan. On last trading day Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) decreased -8.06% to close at $36.03. Its volatility for the week is 6.76% while volatility for the month is 5.19%. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) monthly performance is -27.82%.